REG - Oxford Biomedica PLC - Update on CDMO Services

Oxford BioMedicaAnnouncement

20/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240320:nRST4894Ha&default-theme=true

RNS Number : 4894H  Oxford Biomedica PLC  20 March 2024

 

Oxford Biomedica Provides Update on CDMO Services Including New Commercial
Agreement

-     New and expanded contracts highlight commercial momentum across all
viral vector types

 

-     OXB now working on multiple late-stage programmes with its portfolio
of client programmes progressing to later stage work

 

 

Oxford, UK - 20, March, 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and
gene therapy CDMO, today provides an update on its CDMO services activity.

Year to date, Oxford Biomedica has experienced consistently strong demand for
its CDMO services across all key viral vector types, with its portfolio of
client programmes transitioning towards later stage work. As a result of
commercial developments set out below, OXB is now working on three late-stage
programmes.

Recently, the Company signed a contract with a new undisclosed US-based
biotechnology company for the manufacture of lentiviral vectors as the client
prepares for the commercial launch of its CAR-T programme targeting multiple
myeloma. Manufacturing will take place in Oxbox, the Company's Oxford-based
manufacturing facility.

Alongside this, Oxford Biomedica has signed two new programmes with existing
clinical-stage clients for projects including Process Development and GMP
manufacturing.

Furthermore, the Company has signed a new agreement with a US-based client
specialising in cardiac gene therapy for the tech transfer, optimisation and
manufacture of an adeno-associated virus-based process (AAV).

 

Under the terms of these agreements, Oxford Biomedica will receive payments
related to the development and manufacturing of viral vectors for use in
clinical trials in addition to certain development and regulatory milestone
payments. These payments will support the Company in achieving its medium-term
financial guidance announced on 5 March 2024
(https://oxb.com/update-to-medium-term-financial-guidance-and-2023-trading-and-notice-of-preliminary-results/?_gl=1*1hrea5c*_up*MQ..*_ga*OTc3MjIzMjc5LjE3MTA3NTk4OTQ.*_ga_FCQYC8TBF8*MTcxMDc1OTg5NC4xLjEuMTcxMDc1OTg5Ny4wLjAuMA..)
.

 

Dr Sébastien Ribault, Chief Commercial Officer of Oxford Biomedica,
commented: "The signing of a late-stage programme, alongside the continued
expansion of existing agreements since the start of 2024, demonstrates
clients' confidence in OXB's ability to deliver process development and GMP
manufacturing services. Our Business Development team continues to experience
strong demand for process characterisation, validation, and process
performance qualification (PPQ) work, showcasing the high quality and
reliability of our services. This demand is in line with our forecasts across
all key vectors and geographies, validating our growth strategy. We remain
confident about our future prospects as the leading global pure-play CDMO in
cell and gene therapy and our ability to continue building our client
portfolio."

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc:

 

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 1865 509 737 / E:
ir@oxb.com

 

ICR Consilium:

 

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
(mailto:oxfordbiomedica@consilium-comms.com)

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy contract development and manufacturing organisation (CDMO) with a
mission to enable its clients to deliver life changing therapies to patients
around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV), adenoviral vectors, and other viral vector types. Oxford
Biomedica's world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near
Boston, MA, US. Learn more at www.oxb.com (https://www.oxb.com/) , and follow
us on LinkedIn (https://www.linkedin.com/company/oxford-biomedica/) and
YouTube (https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFLFFDVTIALIS